Organisation paid for research Program year 2025 Source: CMS Open Payments

California Neuroscience Research LLC

Neither a doctor nor a teaching hospital

Research payments

$779,747

99 payments

Through program year 2025, California Neuroscience Research LLC is reported as receiving $779,747 in research payments, across 99 payments.

By program year

4 rows
Year Kind Amount Payments
2025 Research $185,453 46
2024 Research $176,228 42
2023 Research $378,170 9
2022 Research $39,897 2

Breakdown

Who paid Research payments · program years 2022–2025
  1. Boehringer Ingelheim Pharmaceuticals, Inc. $386,089 17 payments
  2. Sage Therapeutics, Inc. $272,157 3 payments
  3. Biohaven Pharmaceutical Holding Company Ltd. $52,903 35 payments
  4. Pfizer Inc. $46,112 40 payments
  5. ITI, Inc. $22,486 4 payments
Studies the money was for Research payments · program years 2022–2025
  1. A Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Effects of Sage-718 in Participants With Mild Cognitive Impairment Or Mild Dementia Due to Alzheimer's Disease $272,157 3 payments
  2. PoCC study in patients with PTSD $149,549 3 payments
  3. A 6-week, multi-centre, randomised, double-blind (participant and investigator), placebo-controlled, dose-finding trial to evaluate the efficacy, tolerability, and safety of different doses of oral BI 1569912 in patients with major depressive disorder $140,674 11 payments
  4. A Phase 4 Randomized Doubleblind Placebocontrolled Study to Evaluate the Efficacy and Tolerability of Rimegepant for the Prevention of Migraine in Adults With A History of Inadequate Response to Oral Preventive Medications $69,808 63 payments
  5. Proof of concept and DRF in MDD $50,961 2 payments
  6. Proof of Concept and DRF with TRPC4/5 inhibitor in MDD $44,906 1 payment
  7. A Phase 4 Randomized Doubleblind Placebocontrolled Study to Evaluate the Efficacy and Safety of Rimegepant in Episodic Migraine Prevention With Multiple Dosing Regimens $15,757 5 payments
  8. A Phase 23 Randomized Doubleblind Placebo Controlled Study to Evaluate the Efficacy and Safety of Oral Zavegepant in Migraine Prevention $13,450 7 payments
  9. Iti-007-602 $12,500 3 payments
  10. Iti-007-321 $9,986 1 payment

What you are looking at

A noncovered recipient is an organisation paid for research that is neither an individual clinician nor a teaching hospital — typically a contract research organisation, a foundation or a trial site network. They receive 81% of all reported research money, which is why they appear here at all.

Provenance

Source: CMS Open Payments · through program year 2025

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record